Exelixis, Inc. announced that today it granted a nonstatutory stock option to purchase 32,500 shares of Exelixis common stock and restricted stock units representing an aggregate of 37,750 shares of Exelixis common stock to nine new employees. Continue Reading
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010. Continue Reading
Derycz Scientific, Inc., the content repurposing company, today announced that its subsidiary Reprints Desk, an award-winning provider of information services and content workflow solutions, has launched ePrints NRx, a new scientific article collection service that simplifies the re-use of PDFs by medical marketers, brand managers and sales professionals. Continue Reading
Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Continue Reading
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline’s Advair will remain surveyed pulmonologists’ and primary care physicians’ (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Continue Reading
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research Annual Meeting in Washington, DC. Continue Reading
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer. Continue Reading
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi’s proprietary rxRNA™ technology with Mirna’s microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds. Continue Reading
Astronauts on board Space Shuttle Discovery (STS-131) activated an experiment this morning as part of the ninth scientific payload for Astrogenetix, an Austin, Texas-based commercial biotech company. Astrogenetix is conducting the International Space Station National Laboratory Pathfinder Vaccine (NLP-V) missions to take advantage of the unique conditions of microgravity to uncover changes in bacteria that can be targeted to create new vaccines and therapeutics. Continue Reading
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye Pharmaceutical subsidiary (“Erye”) recently received approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium. Continue Reading
